Cargando…

Novel Treatments Paradigms: Membranous Nephropathy

Primary membranous nephropathy (MN) is a kidney-specific autoimmune glomerular disease and the leading cause of nephrotic syndrome (NS) in White adults, usually caused by antiphospholipase A2 receptor (PLA2R) antibodies, although several new target antigens have been recently identified. It is chara...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas-Rivera, Jorge E., Ortiz, Alberto, Fervenza, Fernando C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014375/
https://www.ncbi.nlm.nih.gov/pubmed/36938069
http://dx.doi.org/10.1016/j.ekir.2022.12.011
_version_ 1784906981181489152
author Rojas-Rivera, Jorge E.
Ortiz, Alberto
Fervenza, Fernando C.
author_facet Rojas-Rivera, Jorge E.
Ortiz, Alberto
Fervenza, Fernando C.
author_sort Rojas-Rivera, Jorge E.
collection PubMed
description Primary membranous nephropathy (MN) is a kidney-specific autoimmune glomerular disease and the leading cause of nephrotic syndrome (NS) in White adults, usually caused by antiphospholipase A2 receptor (PLA2R) antibodies, although several new target antigens have been recently identified. It is characterized by the diffuse thickening of the glomerular basement membrane secondary to immune complex deposition. In patients with persistent NS without response to maximizing conservative therapy including the use of renin-angiotensin system (RAS) blockers, the use of immunosuppressive agents is warranted. However, the optimal immunosuppressive treatment has not yet been established. Classical immunosuppressants, such as cyclophosphamide plus steroids, are effective but may cause clinically relevant adverse effects, limiting their use. Rituximab offers efficacy with a better safety profile whereas calcineurin inhibitors (CNIs) are marred by high relapse rates and nephrotoxicity. Nevertheless, up to 30% of patients fail to respond to standard therapy. Novel and specific therapies targeting B cells and plasma cells have shown encouraging preliminary results, in terms of clinical efficacy and safety profile, especially in patients with poor tolerance or refractory to conventional treatments. In this brief review, we discuss the benefits and limitations of the current therapeutic approach to MN and describe emerging novel therapies that target its pathogenesis.
format Online
Article
Text
id pubmed-10014375
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100143752023-03-16 Novel Treatments Paradigms: Membranous Nephropathy Rojas-Rivera, Jorge E. Ortiz, Alberto Fervenza, Fernando C. Kidney Int Rep Review Primary membranous nephropathy (MN) is a kidney-specific autoimmune glomerular disease and the leading cause of nephrotic syndrome (NS) in White adults, usually caused by antiphospholipase A2 receptor (PLA2R) antibodies, although several new target antigens have been recently identified. It is characterized by the diffuse thickening of the glomerular basement membrane secondary to immune complex deposition. In patients with persistent NS without response to maximizing conservative therapy including the use of renin-angiotensin system (RAS) blockers, the use of immunosuppressive agents is warranted. However, the optimal immunosuppressive treatment has not yet been established. Classical immunosuppressants, such as cyclophosphamide plus steroids, are effective but may cause clinically relevant adverse effects, limiting their use. Rituximab offers efficacy with a better safety profile whereas calcineurin inhibitors (CNIs) are marred by high relapse rates and nephrotoxicity. Nevertheless, up to 30% of patients fail to respond to standard therapy. Novel and specific therapies targeting B cells and plasma cells have shown encouraging preliminary results, in terms of clinical efficacy and safety profile, especially in patients with poor tolerance or refractory to conventional treatments. In this brief review, we discuss the benefits and limitations of the current therapeutic approach to MN and describe emerging novel therapies that target its pathogenesis. Elsevier 2023-01-02 /pmc/articles/PMC10014375/ /pubmed/36938069 http://dx.doi.org/10.1016/j.ekir.2022.12.011 Text en © 2022 Published by Elsevier Inc. on behalf of the International Society of Nephrology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Rojas-Rivera, Jorge E.
Ortiz, Alberto
Fervenza, Fernando C.
Novel Treatments Paradigms: Membranous Nephropathy
title Novel Treatments Paradigms: Membranous Nephropathy
title_full Novel Treatments Paradigms: Membranous Nephropathy
title_fullStr Novel Treatments Paradigms: Membranous Nephropathy
title_full_unstemmed Novel Treatments Paradigms: Membranous Nephropathy
title_short Novel Treatments Paradigms: Membranous Nephropathy
title_sort novel treatments paradigms: membranous nephropathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014375/
https://www.ncbi.nlm.nih.gov/pubmed/36938069
http://dx.doi.org/10.1016/j.ekir.2022.12.011
work_keys_str_mv AT rojasriverajorgee noveltreatmentsparadigmsmembranousnephropathy
AT ortizalberto noveltreatmentsparadigmsmembranousnephropathy
AT fervenzafernandoc noveltreatmentsparadigmsmembranousnephropathy